多发性骨髓瘤实验室检查特点

doi:10.3969/j.issn.1673-8640.2015.08.018

摘要/Abstract

摘要：

多发性骨髓瘤(MM)是一种浆细胞单克隆恶性增生性疾病。其骨髓瘤细胞浸润骨骼和软组织,产生M蛋白,引起骨质破坏、贫血、肾功能不全、反复感染等。经统计,在所有恶性肿瘤中MM的发病率占到约1%,而在血液系统恶性肿瘤中其发病率超过10%。其发病机制尚不完全清楚,临床症状复杂多样,极易误诊或漏诊。同时实验室检查指标差别也较大,导致MM的诊断和鉴别诊断困难。因此,探讨MM的临床、实验室诊断特点对MM的早期发现、早期诊断和早期治疗具有很大的临床意义。文章就MM的临床和实验室诊断特点做一综述。

关键词: 多发性骨髓瘤, 实验室检查, 诊断

Abstract:

Multiple myeloma(MM) is a plasma cell monoclonal malignant proliferative disease. The myeloma cells infiltrate bone and soft tissue, produce M protein and cause bone destruction, anemia, renal insufficiency, repeated infection and so on. Through the statistics, the incidence of MM in all malignant tumors accounts for about 1%, and its incidence in blood system of malignant tumor is more than 10%.The pathogenesis of MM is not fully clear, the complex and various clinical symptoms lead to misdiagnosis or missed diagnosis easily. The difference of laboratory examination may lead to difficult disease diagnosis and differential diagnosis. Therefore, investigating the clinical and laboratory diagnosis characteristics of MM has clinical significance for the early detection, early diagnosis and early treatment of MM. In this paper, the clinical and laboratory diagnosis characteristics of MM are reviewed in detail.

Key words: Multiple myeloma, Laboratory examination, Diagnosis

中图分类号:

R446.11

汪薇. 多发性骨髓瘤实验室检查特点[J]. 检验医学, 2015, 30(8): 847-851.

WANG Wei.. The laboratory characteristics of multiple myeloma[J]. Laboratory Medicine, 2015, 30(8): 847-851.

参考文献 39

[1]	KYLE RA, RAJKUMAR SV.Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma[J]. Leukemia, 2009, 23(1): 3-9.
[2]	KRISTINSSON SY, LANDGREN O, DICKMAN PW, et al.Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003[J]. J Clin Oncol, 2007, 25(15): 1993-1999.
[3]	KYLE RA, RAJKUMAR SV.Multiple myeloma[J]. N Engl J Med, 2004, 351(18):1860-1873.
[4]	JAFFE ES, HARRIS NL, STEIN H, et al.Pathology and genetics of tumours of haematopoietic and lymphoid tissues[J]. Lyon: IARC Press, 2001: 144.
[5]	王鸿利. 多发性骨髓瘤实验诊断的进展[J].临床内科杂志,2007,24(9):581-583.
[6]	陈世伦. 多发性骨髓瘤的实验室检查[J].中国全科医学,2007,10(20):1669-1672.
[7]	姜波,蒋志勇,张海军.多发性骨髓瘤的实验室特点及误诊分析[J].临床输血与检验,2010,12(3):268-269.
[8]	周胜玉,蔡晓燕.血红蛋白水平对多发性骨髓瘤预后的影响[J].临床和实验医学杂志,2008,7(4):39-41.
[9]	邓书会,徐燕,麦玉洁,等.122例多发性骨髓瘤患者ISS分期分析与DS分期、IFM分期的比较[J].中华血液学杂志,2008,29(4):217-221.
[10]	JACOBSON JL,HUSSEIN MA,BARLOGIE B,et al.A new staging system for multiple myeloma patients based on the Southwest Oncology Group(SWOG) experience[J].Br J Haematol,2003,122(3):441-450.
[11]	BLADÉ J, ROSIÑOL L. Renal, hematologic and infectious complications in multiple myeloma[J]. Best Pract Res Clin Haematol, 2005, 18(4): 635-652.
[12]	HERRERA GA, JOSEPH L, GU X, et al . Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia[J]. Arch Pathol Lab Med, 2004 , 128(8) : 875-879.
[13]	RESIC H,MATARADZIJA A,KUKAVICA N, et al.Renal function in patients with multiple myeloma[J]. Bantao J,2009,7(1):22-25.
[14]	李增军,许洪志,徐健.多发性骨髓瘤的误诊分析[J].山东医药,2003,43(25):59.
[15]	李斯丹,徐燕,王亚非,等.多发性骨髓瘤骨病的临床特点分析[J].中华血液学杂志,2010,31(4):2012-2032.
[16]	葛祥花. 多发性骨髓瘤患者β2-微球蛋白、C 反应蛋白水平的测定及临床意义[J].临床血液学杂志,2003,17(5):242-243.
[17]	DURIE BG, STROCK-NOVACK D, SALMON SE, et al.Prognostic value of pretreatment serum beta2 miccroglobulin in myeloma: a Southwest Oncology Group Study[J]. Blood, 1990, 75(4): 823-830.
[18]	GREIPP PR,SAN MIQUEL J,DURIE BG,et al.International staging system for multiple myeloma[J].J Clin Oncol,2005,23(15):3412-3420.
[19]	李勇华,侯健,王东星,等.沙立度胺治疗多发性骨髓瘤疗效影响因素分析[J].中华内科杂志,2006,45(7):587-589.
[20]	BEETHAM R.Detection of Bence-Jones protein in practice[J]. Ann Clin Biochem, 2000, 37(Pt 5):563-570.
[21]	VAN RHEE F,BOLEJACK V,HOLLMIG K,et al.High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis[J].Blood,2007,110(3):827-832.
[22]	MEAD GP, CARR-SMITH HD, DRAYSON MT, et al.Serum free light chains for monitoring multiple myeloma[J].Br J Haematol,2004,126(3):348-354.
[23]	WALDENSTROM J.Studies on conditions associated with disturbed gamma globulin formation(gammopathies)[J].Harvey Lect,1960,56:211-231.
[24]	HUSSEIN MA,JUTURI JV,LIEBERMAN I.Multiple myeloma:present and future[J].Curr Opin Oncol,2002,14(1):31-35.
[25]	HUGHES M,DAVIDSON DF,MCCOLL M.Outcomes of discretionary laboratory requesting of serum protein electrophoresis[J].Ann Clin Biochem,2006,43(Pt 5):372-374.
[26]	崔凡. 免疫固定电泳检查在多发性骨髓瘤中的应用[J].临床和实验医学杂志,2008,7(1):33-34.
[27]	刘汐盈,孙淑艳,宋媛媛.血清免疫固定电泳、蛋白电泳、免疫球蛋白及轻链定量对多发性骨髓瘤临床诊断价值探讨[J].中国实验诊断学,2010,14(5):680-681.
[28]	DIERLAMM T,LAACK E,DIERLAMM J,et al.IgM myeloma:a report of four cases[J].Ann Hematol,2002,81(3):136-139.
[29]	ELAINE SJ,NANCY L H,HARALD S,et al.Pathology and genetics of tumours of haematopoietic and lymphoid tissues[M].周小鸽,陈辉树,主译.北京:人民卫生出版社,2006:152-155.
[30]	周萍,唐吉斌,曹春鸾,等.62例多发性骨髓瘤的髓象分析[J].安徽医药,2011,15(2):203-204.
[31]	江继发, 程玮. 17 例多发性骨髓瘤临床分析[J].安徽医药,2008, 12(6) : 531-532.
[32]	ISHIKAWA H,TSUYAMA N,KAWANO MM.Interleukin-6-induced proliferation of human myeloma cell associated with CD45 moloeules[J].Int J Hematol,2003,78(2):95-105.
[33]	刘莉. 116例多发性骨髓瘤免疫特征表型分析[J].检验医学与临床,2013,10(10):1249-1250.
[34]	TRCIC RL, SKELIN IK, SUSTERCIC D, et al.Cytogenetics of multiple myeloma[J].Coll Antropol,2010,34(1):41-44.
[35]	CHANG H,TRIEU Y,QI X,et al.Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: adverse effect of 1q21 gains[J].Leuk Res,2011,35(1):95-98.
[36]	FONSECA R,BLOOD E,RUE M,et al.Clinical and biologic implications of recurrent genomic aberrations in myeloma[J].Blood,2003,101(11):4569-4575.
[37]	中华医学会血液学分会.多发性骨髓瘤骨病诊治指南[J].中华血液学杂志,2011,32(10):721-723.
[38]	周莉莉. 骨髓瘤的骨质破坏发生机制研究进展[J].中国实验血液学杂志,2007,15(6):1340-1344.
[39]	PALUMBO A,ANDERSON K.Multiple myeloma[J].N Engl J Med,2011,364(11):1046-1060.